Yuanyuan Wang

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 342 citations

Phase 3B, Treatment And Prevention, Clinical Epidemiology +10

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond et al. · The Lancet HIV · 2021 · 130 citations

Phase 3B, Treatment And Prevention, Clinical Epidemiology +10

Preconception diabetes mellitus and adverse pregnancy outcomes in over 6.4 million women: A population-based cohort study in China

Yumei Wei, Qin Xu, Huixia Yang et al. · PLoS Medicine · 2019 · 114 citations · Full text

Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease

Jie Tong, Dongjie Li, Hongbo Meng et al. · Acta Pharmaceutica Sinica B · 2022 · 92 citations · Full text

Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled Trial

Liang Zheng, Yaoliang Lai, Weimin Lu et al. · Clinical Gastroenterology and Hepatology · 2015 · 70 citations

Functional Gastrointestinal Disorder, Gastrointestinal Pharmacology, Medicine +8